Eliem Therapeutics (ELYM) Short Interest Ratio & Short Volume → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free ELYM Stock Alerts $8.68 +0.27 (+3.21%) (As of 11:18 AM ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Eliem Therapeutics Short Interest DataCurrent Short Volume56,700 sharesPrevious Short Volume601,100 sharesChange Vs. Previous Month-90.57%Dollar Volume Sold Short$402,003.00Short Interest Ratio / Days to Cover0.1Last Record DateApril 30, 2024Outstanding Shares27,720,000 sharesFloat Size18,440,000 sharesShort Percent of Float0.31%Today's Trading Volume70,222 sharesAverage Trading Volume602,928 sharesToday's Volume Vs. Average12% Short Selling Eliem Therapeutics ? Sign up to receive the latest short interest report for Eliem Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatELYM Short Interest Over TimeELYM Days to Cover Over TimeELYM Percentage of Float Shorted Over Time Ad Paradigm PressBiden to Drop BOMBSHELL June 13th?Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th!Click here now to see his shocking evidence. Eliem Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202456,700 shares $402,003.00 -90.6%0.3%0.1 $7.09 4/15/2024601,100 shares $2.86 million +4,453.8%3.3%0.9 $4.75 3/31/202413,200 shares $36,168.00 +1.5%0.1%1.2 $2.74 3/15/202413,000 shares $35,100.00 +19.3%0.1%1.9 $2.70 2/29/202410,900 shares $29,757.00 +12.4%0.1%1.1 $2.73 2/15/20249,700 shares $25,705.00 +1.0%0.1%1 $2.65 Get the Latest News and Ratings for ELYM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20249,600 shares $24,576.00 +1.1%0.1%0.8 $2.56 1/15/20249,500 shares $25,840.00 -23.4%0.1%0.8 $2.72 12/31/202312,400 shares $33,480.00 -46.8%0.1%1 $2.70 12/15/202323,300 shares $63,609.00 -30.7%0.1%1.5 $2.73 11/30/202333,600 shares $86,016.00 -4.8%0.2%2.5 $2.56 11/15/202335,300 shares $88,250.00 -14.9%0.2%2.3 $2.50 10/31/202341,500 shares $109,145.00 +4.8%0.2%2.7 $2.63 10/15/202339,600 shares $103,356.00 -0.5%0.2%2.3 $2.61 9/30/202339,800 shares $104,674.00 +6.7%0.2%1.1 $2.63 9/15/202337,300 shares $101,083.00 -14.1%0.2%1.1 $2.71 8/31/202343,400 shares $115,010.00 -18.4%0.2%1.4 $2.65 8/15/202353,200 shares $142,044.00 -15.2%0.3%1.9 $2.67 7/31/202362,700 shares $168,036.00 +91.7%0.4%2.3 $2.68 7/15/202332,700 shares $92,541.00 +1.9%0.2%1.3 $2.83 6/30/202332,100 shares $89,880.00 +3.2%0.2%4.6 $2.80 6/15/202331,100 shares $87,702.00 -16.6%0.2%4.9 $2.82 5/31/202337,300 shares $108,916.00 +98.4%0.2%5 $2.92 5/15/202318,800 shares $56,024.00 -5.5%0.1%1.3 $2.98 4/30/202319,900 shares $62,486.00 +33.6%0.1%1.2 $3.14 4/15/202314,900 shares $46,935.00 -39.4%0.1%0.8 $3.15 3/31/202324,600 shares $71,340.00 +25.5%0.1%1.5 $2.90 3/15/202319,600 shares $59,584.00 -55.2%0.1%1 $3.04 2/28/202343,700 shares $155,572.00 +39.6%0.3%2.5 $3.56 2/15/202331,300 shares $79,815.00 +16.4%0.2%2.3 $2.55 1/31/202326,900 shares $94,150.00 +28.1%0.2%3.6 $3.50 1/15/202321,000 shares $85,365.00 +81.0%0.1%3 $4.07 12/30/202211,600 shares $42,572.00 -95.1%0.1%1.6 $3.67 12/15/2022238,500 shares $624,870.00 -0.2%1.3%31 $2.62 11/30/2022238,900 shares $611,584.00 -0.2%1.4%26.5 $2.56 11/15/2022239,300 shares $720,293.00 -0.1%1.4%15.4 $3.01 10/31/2022239,600 shares $783,492.00 -0.5%1.4%11 $3.27 10/15/2022240,800 shares $852,432.00 -0.7%1.4%8.6 $3.54 9/30/2022242,600 shares $783,598.00 -2.9%1.4%6.4 $3.23 9/15/2022249,900 shares $797,181.00 +1.7%1.4%5 $3.19Look Who Fired the World’s Richest Man (Ad)This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S. And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman.Get the full story here. ELYM Short Interest - Frequently Asked Questions What is Eliem Therapeutics' current short interest? Short interest is the volume of Eliem Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 56,700 shares of ELYM short. 0.31% of Eliem Therapeutics' shares are currently sold short. Learn More on Eliem Therapeutics' current short interest. What is a good short interest percentage for Eliem Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.31% of Eliem Therapeutics' floating shares are currently sold short. Is Eliem Therapeutics' short interest increasing or decreasing? Eliem Therapeutics saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 56,700 shares, a decline of 90.6% from the previous total of 601,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Eliem Therapeutics' float size? Eliem Therapeutics currently has issued a total of 27,720,000 shares. Some of Eliem Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Eliem Therapeutics currently has a public float of 18,440,000 shares. How does Eliem Therapeutics' short interest compare to its competitors? 0.31% of Eliem Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Eliem Therapeutics: RAPT Therapeutics, Inc. (9.23%), Inozyme Pharma, Inc. (8.23%), XOMA Co. (2.33%), XBiotech Inc. (3.88%), Xeris Biopharma Holdings, Inc. (6.50%), CytomX Therapeutics, Inc. (4.62%), Enanta Pharmaceuticals, Inc. (14.15%), Verastem, Inc. (3.49%), Nektar Therapeutics (1.99%), Akebia Therapeutics, Inc. (5.66%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Eliem Therapeutics stock? Short selling ELYM is an investing strategy that aims to generate trading profit from Eliem Therapeutics as its price is falling. ELYM shares are trading up $0.27 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Eliem Therapeutics? A short squeeze for Eliem Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ELYM, which in turn drives the price of the stock up even further. How often is Eliem Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ELYM, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: RAPT Short Squeeze INZY Short Squeeze XOMA Short Squeeze XBIT Short Squeeze XERS Short Squeeze CTMX Short Squeeze ENTA Short Squeeze VSTM Short Squeeze NKTR Short Squeeze AKBA Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ELYM) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals